Literature DB >> 19300879

Interest of the new criteria for drug trials in AD.

B Dubois1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19300879     DOI: 10.1007/s12603-009-0042-9

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN: 1279-7707            Impact factor:   4.075


× No keyword cloud information.
  6 in total

1.  Mild cognitive impairment: clinical characterization and outcome.

Authors:  R C Petersen; G E Smith; S C Waring; R J Ivnik; E G Tangalos; E Kokmen
Journal:  Arch Neurol       Date:  1999-03

2.  Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study.

Authors:  M Sarazin; C Berr; J De Rotrou; C Fabrigoule; F Pasquier; S Legrain; B Michel; M Puel; M Volteau; J Touchon; M Verny; B Dubois
Journal:  Neurology       Date:  2007-11-06       Impact factor: 9.910

Review 3.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

4.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.

Authors:  William E Klunk; Henry Engler; Agneta Nordberg; Yanming Wang; Gunnar Blomqvist; Daniel P Holt; Mats Bergström; Irina Savitcheva; Guo-feng Huang; Sergio Estrada; Birgitta Ausén; Manik L Debnath; Julien Barletta; Julie C Price; Johan Sandell; Brian J Lopresti; Anders Wall; Pernilla Koivisto; Gunnar Antoni; Chester A Mathis; Bengt Långström
Journal:  Ann Neurol       Date:  2004-03       Impact factor: 10.422

Review 5.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria.

Authors:  Bruno Dubois; Howard H Feldman; Claudia Jacova; Steven T Dekosky; Pascale Barberger-Gateau; Jeffrey Cummings; André Delacourte; Douglas Galasko; Serge Gauthier; Gregory Jicha; Kenichi Meguro; John O'brien; Florence Pasquier; Philippe Robert; Martin Rossor; Steven Salloway; Yaakov Stern; Pieter J Visser; Philip Scheltens
Journal:  Lancet Neurol       Date:  2007-08       Impact factor: 44.182

6.  Amnestic MCI or prodromal Alzheimer's disease?

Authors:  Bruno Dubois; Martin L Albert
Journal:  Lancet Neurol       Date:  2004-04       Impact factor: 44.182

  6 in total
  3 in total

1.  Imaging and biomarkers will be used for detection and monitoring progression of early Alzheimer's disease.

Authors:  M W Weiner
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

2.  Use of biomarkers in Alzheimer's trials.

Authors:  B Vellas
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

3.  Measuring cognitive change in subjects with prodromal Alzheimer's disease.

Authors:  T Mura; C Proust-Lima; H Jacqmin-Gadda; T N Akbaraly; J Touchon; B Dubois; C Berr
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-07-09       Impact factor: 10.154

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.